UK's Latest Cancer Drug Cull Draws Renewed Calls For NICE Reform
This article was originally published in The Pink Sheet Daily
Executive Summary
New cuts to publicly funded British NHS oncology treatments trigger fresh criticisms of the government's Cancer Drugs Fund and renewed calls for a system-wide overhaul of the way cancer drugs are commissioned in the country. Roche CEO suggests company may opt out of conducting trials in UK.